Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov 3;7(11):e014503.
doi: 10.1136/bmjopen-2016-014503.

Dissemination of 2014 dual antiplatelet therapy (DAPT) trial results: a systematic review of scholarly and media attention over 7 months

Melissa K Sharp  1   2   3 , Romana Haneef  2   3   4 , Philippe Ravaud  1   2   3   4   5 , Isabelle Boutron  2   3   4   5
Affiliations

Dissemination of 2014 dual antiplatelet therapy (DAPT) trial results: a systematic review of scholarly and media attention over 7 months

Melissa K Sharp et al. BMJ Open. .

Abstract

Objective: To explore how the results from the 2014 dual antiplatelet therapy (DAPT) trial were disseminated to the scientific community and online media.

Design: A a systematic review of scholarly and public attention surrounding the DAPT study.

Settings: Data were collected from the ISI Web of Knowledge, Google Scholar, PubMed Commons, EurekAlert, the DAPT study website (www.daptstudy.org) and the New England Journal of Medicine website (for scholarly attention) and Altmetric Explorer, Snap Bird, YouTube (for public attention) citing DAPT study results appearing from 16 November 2014 to 10 June 2015.

Participants: No participants were involved in this study.

Main outcome measure: Proportion of contents highlighting the increased risk of mortality and critical to the author's interpretation of the results.

Results: We identified 425 items reported by seven sources; 164 (39%) disseminated the authors' interpretation via an electronic link or a reference, with no additional text. Among 81 items (19 %), the message favoured prolonged treatment and consequently overstated the article conclusions. Among 119 items (28 %), the text was uncertain about the benefit of prolonged treatment but was reported with no or inappropriate mention of increased risk of mortality. Only 34 items (8 %) were uncertain about the benefit of prolonged treatment and mentioned increased risk of mortality. In all, 27 items (6 %) did not favour prolonged treatment, and only 12 of these (3 %) clearly raised some concerns about the reporting of increased risk of death.

Conclusion: Dissemination of the DAPT study results to the scientific community and on different media sources rarely criticised the interpretation of the study results.

Keywords: Dapt therapy; critical opinion; misleading interpretation; mortality; public attention.

PubMed Disclaimer

Conflict of interest statement

Competing interests: 1.Isabelle Boutron is deputy director of the French Equator centre and coordinator of the MiRoR (Methods in Research on Research) project funded by the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 676207. 2.Phlippe Ravaud is member of the steering committee of the Equator network and director of the French Equator centre. 3.Melissa Sharp is fellow in the MiRoR (Methods in Research on Research Project) funded by the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 676207.

Figures

Figure 1
Figure 1
Flow diagram of identified scholarly and public attention surrounding the dual antiplatelet therapy (DAPT) study.
Figure 2
Figure 2
Content of scholarly and public attention surrounding the dual antiplatelet therapy study (n=425).
Figure 3
Figure 3
Content of scholarly and public attention surrounding the dual antiplatelet therapy (DAPT) study by source (n=425).
See this image and copyright information in PMC

References

    1. Wilson WM. Advances in coronary stent technology: current expectations and new developments. Res Rep Clin Cardiol 2013;4:85–96.
    1. Mozaffarian D, Benjamin EJ, Go AS, et al. . Heart disease and stroke statistics–2015 update: a report from the American Heart Association. Circulation 2015;131:e29–322. 10.1161/CIR.0000000000000152 - DOI - PubMed
    1. Palmerini T, Dangas G, Mehran R, et al. . Predictors and implications of stent thrombosis in non-ST-segment elevation acute coronary syndromes: the ACUITY trial. Circ Cardiovasc Interv 2011;4:577–84. 10.1161/CIRCINTERVENTIONS.111.963884 - DOI - PubMed
    1. Palmerini T, Benedetto U, Bacchi-Reggiani L, et al. . Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and bayesian network meta-analysis of randomised trials. Lancet 2015;385:2371–82. 10.1016/S0140-6736(15)60263-X - DOI - PubMed
    1. Spencer FA, Prasad M, Vandvik PO, et al. . Longer-versus shorter-duration dual-antiplatelet therapy after drug-elutingstent placementa systematic review and meta-analysisduration of dual-antiplatelet therapy after drug-eluting stents. Ann Intern Med 2015;163:118–26. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources